

A Comparison of SF-36 and SF-12 Composite Scores and Subsequent Hospitalization and Mortality Risks in Long-Term Dialysis Patients

Eduardo Lacson, Jr., Jianglin Xu, Shu-Fang Lin, Sandie Guerra Dean, J. Michael Lazarus, and Raymond M. Hakim

Fresenius Medical Care North America, Waltham, Massachusetts

Background and objectives: The Short Form 12 (SF-12) has not been validated for long-term dialysis patients. The study compared physical and mental component summary (PCS/MCS) scores from the SF-36 with those from the embedded SF-12 in a national cohort of dialysis patients.

Design, setting, participants, & measurements: All 44,395 patients who had scorable SF-36 and SF-12 from January 1, 2006, to December 31, 2006, and were treated at Fresenius Medical Care, North America facilities were included. Death and first hospitalization were followed for up to 1 year from the date of survey. Correlation and agreement were obtained between PCS-36 and PCS-12 and MCS-36 and MCS-12; then Cox models were constructed to compare associated hazard ratios (HRs) between them.

Results: Physical and mental dimensions both exhibited excellent intraclass correlation coefficients of 0.94. Each incremental point for both PCS-12 and PCS-36 was associated with a 2.4% lower adjusted HR of death and 0.4% decline in HR for first hospitalization (both $P < 0.0001$). Corresponding improvement in HR of death for each MCS point was 1.2% for MCS-12 and 1.3% for MCS-36, whereas both had similar 0.6% lower HR for hospitalization per point (all $P < 0.0001$).

Conclusions: The use of the SF-12 alone or as part of a larger survey is valid in dialysis patients. Composite scores from the SF-12 and SF-36 have similar prognostic association with death and hospitalization risk. Prospective longitudinal studies of SF-12 surveys that consider responsiveness to specific clinical, situational, and interventional changes are needed in this population.

Clin J Am Soc Nephrol 5: 252–260, 2010. doi: 10.2215/CJN.07231009

The medical outcome survey Short Form 36 (SF-36) has been widely used and validated as a quality of life (QoL) assessment tool for the general population and in various subpopulations (1), including patients who have ESRD and are on dialysis (2–14). These studies have shown that physical (PCS) and mental component summary (MCS) scores from the SF-36 are significantly associated with clinical indicators (e.g., hemoglobin, albumin, dialysis dosage), morbidity, and mortality in the dialysis population, even after adjustment for case mix and other factors; however, Ware *et al.* (15) have since used regression methods to select 12 of the 36 items that are covered by the SF-36 to reproduce the PCS and MCS scores. The shortened questionnaire, known as the SF-12, required only one third of the usual time for completion of the SF-36, with the trade-off being loss of information from eight domain scores, namely general health, vitality, physical functioning, role-physical, bodily pain, social functioning, role-emotional, and mental health (1,16). Direct comparisons between both

PCS-36 and PCS-12 and between MCS-36 and MCS-12 have indicated very good correlation and agreement in the general population (15,17), the elderly (18), and some specific subpopulations, including patients with rheumatoid arthritis (19) and ischemic stroke (20) and after myocardial infarction (21).

The SF-12 has not been validated specifically for patients who are on long-term dialysis, although it was used in lieu of the SF-36 in two small studies (22,23). We also found a study that reported mean SF-12 component scores from 38 dialysis patients (from a larger cohort of patients with chronic kidney disease) as part of the recently developed Kidney Disease Quality of Life-36 (KDQoL-36) (24). Furthermore, information regarding any association between morbidity and mortality rates with SF-12 component scores in this population is lacking. This cross-sectional study aimed to measure agreement between the SF-36 and the embedded SF-12 in a large, contemporary, nationally distributed population of long-term dialysis patients. In addition, we compared implications of PCS and MCS derived from both methods on the basis of their respective associations with hazard rates for hospitalization and death.

Received October 12, 2009. Accepted November 18, 2009.

Published online ahead of print. Publication date available at www.cjasn.org.

Correspondence: Dr. Eduardo Lacson, Jr., Clinical Sciences, Epidemiology, and Research, Fresenius Medical Care, North America, 920 Winter Street, Waltham, MA 02451-1457. Phone: 781-699-9000, ext. 2974; Fax: 781-699-4303; E-mail: elacsonj@fmc-na.com

Materials and Methods

Study Population

An automated reminder alerts the social worker to offer the SF-36 survey to all patients who initiate dialysis therapy in Fresenius Medical Care, North America (FMCNA) facilities after their 45th day and upon completion (or refusal to participate) at 6-mo intervals thereafter. Be-

Table 1. Overview of SF-36 and embedded SF-12, with SF-36 scales and marks for questions with major contributions to each of the PCS and MCS scores

SF-12	SF-36 Questions Grouped by Domain	Domains	PCS	MCS
	#2 Health now <i>versus</i> 1 year ago (or other time frame)	NA		
	#3 Limitation in vigorous activities	Physical functioning	<input checked="" type="checkbox"/>	
<input checked="" type="checkbox"/>	#4 Limitation in moderate activities	Physical functioning	<input checked="" type="checkbox"/>	
	#5 Limitation to lift/carry groceries	Physical functioning	<input checked="" type="checkbox"/>	
<input checked="" type="checkbox"/>	#6 Limitation to climb several flights	Physical functioning	<input checked="" type="checkbox"/>	
	#7 Limitation to climb one flight	Physical functioning	<input checked="" type="checkbox"/>	
	#8 Limitation to bend/kneel/stoop	Physical functioning	<input checked="" type="checkbox"/>	
	#9 Limitation to walk >1 mile	Physical functioning	<input checked="" type="checkbox"/>	
	#10 Limitation to walk several blocks	Physical functioning	<input checked="" type="checkbox"/>	
	#11 Limitation to walk one block	Physical functioning	<input checked="" type="checkbox"/>	
	#12 Limitation to bathe/dress self	Physical functioning	<input checked="" type="checkbox"/>	
	#13 Health cut down time for work/activities	Role (limitation) physical	<input checked="" type="checkbox"/>	
<input checked="" type="checkbox"/>	#14 Accomplished less due to health	Role (limitation) physical	<input checked="" type="checkbox"/>	
<input checked="" type="checkbox"/>	#15 Health limited work/activities	Role (limitation) physical	<input checked="" type="checkbox"/>	
	#16 Difficulty performing work/activities	Role (limitation) physical	<input checked="" type="checkbox"/>	
	#21 Pain severity	Bodily pain	<input checked="" type="checkbox"/>	
<input checked="" type="checkbox"/>	#22 Pain interfered with work/activities	Bodily pain	<input checked="" type="checkbox"/>	
<input checked="" type="checkbox"/>	#1 Rate general health	General health	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
	#33 Get sick easier than other people	General health	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
	#34 As healthy as anybody I know	General health	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
	#35 Health expected to get worse	General health	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
	#36 Am in excellent health	General health	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
	#23 Proportion of time full of pep	Vitality	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
<input checked="" type="checkbox"/>	#27 Proportion of time with a lot of energy	Vitality	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
	#29 Proportion of time feeling worn out	Vitality	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
	#31 Proportion of time feeling tired	Vitality	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
	#17 Emotional problems cut down time for work/activities	Role (limitation) emotional		<input checked="" type="checkbox"/>
<input checked="" type="checkbox"/>	#18 Accomplished less due to emotional problems	Role (limitation) emotional		<input checked="" type="checkbox"/>
<input checked="" type="checkbox"/>	#19 Not As careful in work/activities as usual	Role (limitation) emotional		<input checked="" type="checkbox"/>
	#20 Health/emotional issues interfering with social activities	Social functioning		<input checked="" type="checkbox"/>
<input checked="" type="checkbox"/>	#32 Proportion of time interfering with social activities	Social functioning		<input checked="" type="checkbox"/>
	#24 Proportion of time being nervous	Mental health		<input checked="" type="checkbox"/>
	#25 Proportion of time feeling down with no cheering up	Mental health		<input checked="" type="checkbox"/>
<input checked="" type="checkbox"/>	#26 Proportion of time feeling calm and peaceful	Mental health		<input checked="" type="checkbox"/>
<input checked="" type="checkbox"/>	#28 Proportion of time feeling downhearted and blue	Mental health		<input checked="" type="checkbox"/>
	#30 Proportion of time being happy	Mental health		<input checked="" type="checkbox"/>

Checkmarks indicate questions included or considered under the specific column heading.

tween January 1, 2006, and December 31, 2006, 80,049 prevalent dialysis patients from approximately 1100 FMCNA-legacy facilities had at least one opportunity to complete the survey. Among them, 44,395 (55%) unique patients had scorable SF-36 and SF-12 responses (*i.e.*, “responders”), forming the basis of this report.

Case-mix information (age, gender, race, diabetes, vintage, and dialysis modality) was collected as of the survey date for both responders and nonresponders; the latter group comprised patients who were

unable to respond (*e.g.*, because of cognitive or language difficulties), were unwilling to respond, had incomplete/unscorable responses, or postponed addressing the survey and never completed it. For responders, age was calculated on the date of survey, whereas vintage was defined as the time elapsed between each patient’s date of first dialysis and the survey date. For nonresponders, we substituted the date that the survey was offered for “survey date.”

For responders, all available laboratory values from routine monthly

Table 2. Patient characteristics of all patients surveyed from January 1 through December 31, 2006

Characteristic	All Patients (n = 80,049)	
	Responders	Nonresponders
Patients (n [%])	44,395 (55)	35,654 (45)
Age (years; mean ± SD)	61.2 ± 15.1	61.7 ± 15.4
Female (n [%])	20,637 (46)	16,571 (46)
White (n [%])	25,287 (57)	18,542 (52)
Diabetes (n [%])	22,445 (51)	18,661 (53)
Vintage (days; mean ± SD)	1086 ± 1248	1148 ± 1290
In-center HD (n [%])	41,621 (94)	33,260 (93)

HD, hemodialysis.

evaluations that were performed by a single laboratory (Spectra Laboratories, Rockleigh, NJ) were averaged for the last 3-months before and leading up to the survey date to include albumin (by bromocresol green method), creatinine, hemoglobin, phosphorus, calcium, ferritin, and transferrin saturation. Dialysis dosage was collected and averaged

during the same period, and hemodialysis (HD) dosage obtained from two-sample variable volume urea kinetic modeling was converted into weekly standardized Kt/V to allow for pooling and analytical compatibility with peritoneal dialysis dosage (25,26). The first hospitalization and mortality (includes withdrawal from dialysis) outcomes were




Figure 1. Frequency distribution curves showing overlap of responder’s survey scores for (A) PCS-36 with PCS-12 and (B) MCS-36 with MCS-12.




Figure 2. Scatter plots showing the linear correlation (r) between PCS-36 with PCS-12 (A) and MCS-36 with MCS-12 (B).

tracked for a follow-up period of up to 1 year from the date of survey. Patients who were lost to follow-up as a result of transplantation, recovery of kidney function, or transfer out of the FMCNA system contributed person-time at risk until their last day before discharge.

SF-36 and SF-12 QoL Scores

The SF-36 summary scores (PCS-36 and MCS-36) range from 0 to 100, with higher scores representing better self-reported health, and they were calculated using standard (US-derived) scoring algorithms from Ware *et al.* (1,16). General health and vitality are domains shared by PCS and MCS. In addition, PCS encompasses physical functioning, role-physical, and bodily pain, whereas MCS includes social functioning, role-emotional, and mental health. The embedded SF-12 uses only 12 questions from the SF-36 to reproduce the PCS and MCS scores that would have been obtained from 35 of 36 questions on the SF-36 (15). An overview of the structure of each survey is provided in Table 1. The SF-12 summary scores (PCS-12 and MCS-12) also range from 0 to 100 and were calculated using the SAS algorithm program from the KDQoL work group, developed for scoring the SF-12 components of the KDQoL-36 (27).

Statistical Analyses

Pearson linear correlation coefficient (r), Spearman rank correlation coefficient (ρ), and intraclass correlation coefficient were calculated for comparison of SF-36 and SF-12 to describe agreement. Pearson correlation coefficients were also determined (1) within subsets of race, gender, and dialysis modality to determine consistency within subgroups and (2) to assess the relationship between SF-36 domain scores

and SF-12 component scores. Cox proportional hazard models were constructed to determine associations between SF-36 component scores individually, with hospitalization as well as mortality rates, both with and without adjustment for case mix and laboratory variables. In parallel, similar models were constructed using SF-12 component scores. A final multivariable model was then constructed with both PCS-36 and MCS-36 as predictor variables and for side-by-side comparison, a second model substituting both PCS-12 and MCS-12 while retaining all of the other variables unchanged. No imputation was attempted for missing values, and all analyses were performed using SAS 9.1.3 (SAS Institute, Cary, NC).

Results

The study cohort of 44,395 patients (55% response rate) had mean age of 61.2 ± 15.1 years; 46% were female, 57% were white, and 51% had diabetes; and mean vintage was approximately 3 years, with the majority (94%) of patients treated with in-center HD. These characteristics, shown in Table 2, were similar to those from 35,654 (45%) nonresponders although statistical comparisons indicate significant differences in all categories at $P < 0.01$ except female gender ($P = 0.9$), a result, in part, of the large sample size. The comparative distributions of SF-36 and SF-12 scores are shown in Figure 1; a slight right shift for PCS-12 *versus* PCS-36 and a slight left-shift for MCS-12 *versus* MCS-36 were noted. The responders' mean PCS-36 and PCS-12 scores were 33.1 ± 10.5 and 35.3 ± 9.8 , respectively, whereas the mean MCS-36 and MCS-12 scores were 48.0 ± 11.2 and 46.9 ± 10.7 , respectively. In addition to the frame shift, we observed skewness at the extremes (skewness parameter for PCS-36 = 0.27, PCS-12 = 0.29, MCS-36 = -0.29, and MCS-12 = -0.25), also shown in Figure 2.

Excellent linear correlation was noted between PCS-36/PCS-12 and MCS-36/MCS-12 measures, with both having the same Pearson coefficients ($r = 0.94$, $P < 0.0001$; Figure 2). Furthermore, the rank order of values were similarly at Spearman $\rho = 0.94$ for both comparisons ($P < 0.0001$). The intraclass correlation coefficient values between both PCS scores and both MCS scores were also at 0.94 ($P < 0.0001$), indicating that scores between these two instruments not only were highly correlated but also had excellent agreement. Additional subset analysis within subgroups of race and gender indicated that $r = 0.94$ consistently, whereas in different dialysis modalities, $r = 0.94$ for in-center HD and $r = 0.95$ for each of peritoneal dialysis and home HD (all $P < 0.0001$); therefore, there was excellent correlation and agreement between PCS-12 and PCS-36 as well as between MCS-12 and MCS-36.

The PCS-12 also exhibited an almost identical correlation profile with that of PCS-36 toward the eight SF-36 domains, which was mirrored when comparing MCS-36 with MCS-12 (Table 3). Because of slight shifts in distribution curves for PCS-12 and MCS-12 evident in both Figures 1 and 2, there were differences in absolute group mean scores compared with the SF-36 among patients who were hospitalized and those who died during the 1-year follow-up period (Table 4); however, the "gap" in mean scores that was observed between patients with and without outcomes was consistent between PCS-36 and PCS-12 or MCS-36 and MCS-12. The

Table 3. Linear correlation coefficients comparing SF-36 and SF-12 component scores

Parameter	PCS-36	PCS-12	MCS-36	MCS-12
PCS-36	1.00	0.94	0.09	0.15
MCS-36	0.09	0.14	1.00	0.94
SF-36 domains				
physical functioning	0.80	0.76	0.14	0.20
role (limitation) physical	0.69	0.70	0.34	0.36
bodily pain	0.65	0.62	0.38	0.41
general health	0.60	0.53	0.43	0.45
vitality	0.55	0.55	0.55	0.53
social functioning	0.47	0.50	0.69	0.65
role (limitation) emotional	0.24	0.26	0.76	0.76
mental health	0.18	0.21	0.83	0.79

Table 4. Average SF-36 and SF-12 scores among patients grouped by observed outcomes, with a follow-up period of up to 1 year from the date of survey

Parameter	Any Hospitalization		Death + Withdrawal from Dialysis	
	Hospitalized (n = 25,526)	Not Hospitalized (n = 18,869)	Died/Withdrew (n = 6472)	Survived (n = 37,417) ^a
PCS-36	31.7 ± 10.2 ^b	35.1 ± 10.7	28.8 ± 9.6 ^b	33.9 ± 10.5
PCS-12	34.0 ± 9.5 ^b	37.0 ± 10.0	31.3 ± 8.9 ^b	36.0 ± 9.8
MCS-36	47.3 ± 11.4 ^b	48.9 ± 10.9	46.2 ± 11.6 ^b	48.3 ± 11.1
MCS-12	46.1 ± 10.8 ^b	47.8 ± 10.4	45.0 ± 10.9 ^b	47.2 ± 10.6

^aSurvivors included patients who transferred elsewhere or were lost to follow-up (e.g., had a kidney transplant).

^b $P < 0.005$ versus corresponding mean scores for patients without this outcome.

differences in means between hospitalized and nonhospitalized patients were 3.4 points for PCS-36 and 3.0 points for PCS-12, whereas it was 1.6 points for MCS-36 and 1.7 points for MCS-12. Similarly, between those who died and survivors, differences were 5.1 points for PCS-36 and 4.7 points for PCS-12 and 2.1 points for MCS-36 and 2.2 points for MCS-12; therefore, although the comparative scores were not exactly the same and the thresholds were different, the ability of either measure to separate between those with desirable outcomes (e.g., survived or not hospitalized) and those with poor outcomes (e.g., died or hospitalized) were statistically significant within either measure, and the magnitude of the difference in scores relative to different outcomes were similar between SF-12 and SF-36.

The risk profiles for mortality when using each of PCS-36, PCS-12, MCS-36, and MCS-12 individually, in unadjusted, case-mix-adjusted, and case-mix- and laboratory-adjusted models are shown in Figure 3. The corresponding risk profiles for hospitalization are shown in Figure 4. The risk profiles are markedly similar between PCS-36 and PCS-12 as well as between MCS-36 and MCS-12. Furthermore, we note more prominent hazard ratios (HRs) associated with PCS than MCS in both the mortality and hospitalization analyses, indicating that PCS was a stronger predictor of these outcomes than MCS. In addition, there seems to be a greater difference in HRs among

categories in models for mortality versus models for hospitalization, indicating that both the PCS and the MCS were more predictive of mortality than hospitalization. When PCS and MCS were combined in a multivariable model (Table 5), SF-36 and SF-12 component scores exhibited virtually identical HRs and the other independent variables in the model similarly had HRs unchanged. Each incremental PCS-12 and PCS-36 point was associated with identical 2.4% lower adjusted HR of death and 0.4% decline in HR for first hospitalization (both $P < 0.0001$). Corresponding improvement in HR of death for each MCS point was 1.2% for MCS-12 and 1.3% for MCS-36, whereas both had a similar 0.6% lower HR for hospitalization per point (all $P < 0.0001$).

Discussion

To our knowledge, this report is the largest cross-sectional study in patients ESRD and with SF-12 and SF-36 information with accompanying risk estimates for hospitalization and mortality. Our survey response rate of 55% compares favorably with 47.6% of the American cohort reported in the Dialysis Outcomes and Practice Pattern Study (DOPPS) (28). The responders' demographic characteristics were similar enough to that of nonresponders, and because the study population was distributed nationally, we believe that these results are potentially generalizable to the US dialysis population. Results indi-




Figure 3. Risk profile from Cox proportional hazard models for time to death using PCS-36 (A), PCS-12 (B), MCS-36 (C), and MCS-12 (D).

cate that group PCS and MCS information derived from SF-12 is highly correlated and is in agreement with those derived from SF-36 in this population. In addition, we show for the first time that implications on hospitalization or mortality HRs derived from SF-36 composite scores are equally applicable to




Figure 4. Risk profile from Cox proportional hazard models for time to first hospitalization using PCS-36 (A), PCS-12 (B), MCS-36 (C), and MCS-12 (D).

SF-12–derived composite scores; therefore, use of PCS-12/MCS-12 in lieu of the PCS-36/MCS-36, either alone or as part of a larger questionnaire (e.g., KDQoL-36), is valid in the US ESRD population.

We confirm that, on average, PCS scores are much lower in patients with ESRD than in the general population (approx-

Table 5. Comparative HRs within similar multivariable Cox models for hospitalization and mortality that contain both PCS and MCS scores as determinant variables in addition to all case-mix and laboratory biomarkers

Per Unit Change in	Hospitalization				Mortality			
	SF-36		SF-12		SF-36		SF-12	
	HR	95% Limits	HR	95% Limits	HR	95% Limits	HR	95% Limits
PCS-36	0.996	0.994 to 0.997	–	–	0.976	0.973 to 0.978	–	–
PCS-12	–	–	0.996	0.994 to 0.997	–	–	0.976	0.973 to 0.979
MCS-36	0.994	0.993 to 0.995	–	–	0.987	0.985 to 0.990	–	–
MCS-12	–	–	0.994	0.993 to 0.995	–	–	0.988	0.985 to 0.990
Age (years)	0.999	0.998 to 1.000	0.999	0.998 to 1.000	1.034	1.032 to 1.036	1.034	1.031 to 1.036
Female ^a	0.986	0.958 to 1.014	0.987	0.959 to 1.015	0.762	0.721 to 0.806	0.765	0.723 to 0.808
Black race ^a	1.006	0.974 to 1.039	1.006	0.973 to 1.037	0.921	0.862 to 0.984	0.917	0.859 to 0.980
Other race ^a	0.918	0.867 to 0.973	0.919	0.867 to 0.973	0.865	0.767 to 0.976	0.865	0.767 to 0.975
Diabetes ^a	0.996	0.968 to 1.024	0.996	0.968 to 1.024	1.024	0.969 to 1.083	1.033	0.977 to 1.092
Vintage (years)	1.000	1.000 to 1.000	1.000	1.000 to 1.000	1.000	1.000 to 1.000	1.000	1.000 to 1.000
In-center HD	1.073	1.010 to 1.141	1.074	1.010 to 1.141	0.923	0.812 to 1.048	0.923	0.812 to 1.048
Calcium (mg/dl)	1.013	0.991 to 1.036	1.014	0.991 to 1.037	1.105	1.055 to 1.156	1.106	1.056 to 1.157
Phosphorus (mg/dl)	1.024	1.012 to 1.036	1.024	1.012 to 1.036	1.200	1.173 to 1.228	1.200	1.173 to 1.228
Albumin (g/dl)	0.713	0.685 to 0.743	0.712	0.685 to 0.742	0.353	0.328 to 0.380	0.351	0.326 to 0.378
Hemoglobin (g/dl)	0.958	0.946 to 0.970	0.958	0.946 to 0.970	0.923	0.901 to 0.946	0.924	0.902 to 0.947
Ferritin (ng/ml)	1.000	1.000 to 1.000	1.000	1.000 to 1.000	1.000	1.000 to 1.000	1.000	1.000 to 1.000
TSAT (%)	0.996	0.994 to 0.997	0.996	0.994 to 0.997	0.994	0.991 to 0.997	0.994	0.991 to 0.997
Creatinine (mg/dl)	0.990	0.983 to 0.997	0.990	0.983 to 0.997	0.914	0.900 to 0.927	0.912	0.899 to 0.926
Standard Kt/V	0.933	0.889 to 0.980	0.933	0.889 to 0.980	0.786	0.712 to 0.867	0.787	0.713 to 0.869

TSAT, transferrin saturation

^aReference group.

mately 17 points less by PCS-36 and approximately 15 points less by PCS-12), consistent with previous reports in large US prevalent dialysis cohorts (2,3,5,6). Similarly, we confirm that average MCS scores are only slightly lower (approximately 3 to 4 points less) than in the general population. Although a decade apart, the distribution of SF-36 PCS and MCS scores from this study almost exactly mirrors that of the FMCNA cohort from 1996 (5). Furthermore, we detected a similar magnitude of decline in adjusted relative risk for death for each 1-point increase in PCS (2.4%) as reported in other large studies: 2.0% from Lowrie *et al.* (5), approximately 2.1% from De Oreo *et al.* (2) (derived from 10.4% decline per 5 points), and 2.1% in the US cohort of DOPPS by Mapes *et al.* (28) (derived from 21% decline per 10 points), for each 1-point increase in PCS. The HR for mortality in this study decreased by 1.3% for each incremental MCS-36 point (with 1.2% for MCS-12) and was most consistent with DOPPS data, which revealed a 1.3% lower HR per 1-point change in MCS (derived from 13% decline per 10 points) (28). Values ranged from a 1.4% decline for each 5-point increase in MCS (De Oreo *et al.*) to a 2% decline for each MCS 1-point increase (Lowrie *et al.*) (2,5); however, significant increases in death risk accrue as soon as PCS-12 falls below 44 (for PCS-36 below 40), whereas a slightly higher risk was associated with MCS-12/36 below 50.

The corresponding decline in hazard rate for first hospitalization was only by 0.4% per incremental PCS point in this study,

slightly lower than the 0.9% lower hazard rate per 1-point increment of PCS from DOPPS (Lowrie *et al.* reported odds ratios for hospitalization and De Oreo *et al.* reported hospital days per patient-year) (2,5,28). The corresponding time to first hospitalization hazard rates were –0.6% lower HR per MCS point in this study and 5% lower HR per 10-point MCS increment in DOPPS. Similarly, hospitalization risk begins to increase at PCS-12/36 below 44 and MCS-12 below 50, whereas for MCS-36, scores up to 59 were associated with increased risk (of borderline significance) in adjusted models. Of note, adjustment for case-mix and laboratory variables had a larger impact on the hazard rates associated with PCS than MCS, perhaps indicative of a stronger correlation between these variables and physical well-being.

Although the PCS and MCS both are known to predict hard outcomes in ESRD, losing information provided by the eight domains of the SF-36 may decrease the ability to detect more specific changes in a patient's functional well-being. For example, one seminal study that showed QoL improvement that resulted from increased hematocrit by the use of recombinant erythropoietin in new dialysis patients would be less impressive if only PCS and MCS were reported, absent the much larger changes detected in vitality, social functioning, mental health, and physical functioning (13). Thus, the usefulness of the SF-12 in isolation will depend on the purpose of investigators, notwithstanding the logistical ease of implementation when compared with the SF-36. The

Centers for Medicare and Medicaid Services Interpretative Guidelines [S&C-09-01, version 1.1, 10/03/08 (29)] memo accompanying the recently updated Conditions for Coverage for ESRD facilities (42 CFR part 494), identified the KDQoL-36 as the preferred standardized physical and mental assessment tool for psychosocial status, on the basis of recommendations from the National Quality Forum and the Centers for Medicare and Medicaid Services Clinical Performance Measures Work Group, with consideration that use of the KDQoL-36 is free from royalty fees. Loss of the eight domain scores will be offset by the addition of kidney disease-specific questions on the burden, symptoms, and effects of kidney disease on daily life (24). In this analysis, we used the scoring algorithm from the KDQoL work group, thereby providing a better understanding of the PCS-12 and MCS-12 that will eventually be obtained from implementing the KDQoL-36 (27).

Taken together, results suggest that the use of SF-12-derived component scores in ESRD are just as good as their SF-36 counterparts. Furthermore, norms and other interpretation guidelines from previous work using the SF-36 in the US dialysis population is useful in interpreting the SF-12. The strengths of this study include results that were robust, a diverse source population with a distribution that is national in scope, a relatively high survey response rate, and a contemporary time period reflecting current dialysis practices and technology; however, the study has several limitations, with the first three of them inherent to the study design: First, this was a cross-sectional study that did not take into account longitudinal changes; second, results obtained with regard to prediction of death and hospitalization hazard rates were not necessarily causal and should be interpreted with caution; third, the strengths of the association observed may have a larger variance when studying groups of a much smaller size. Fourth, this analysis does not necessarily apply to non-US patient populations, although our findings may be true in these populations, as well. Clearly there are international and intercontinental variations in scores and interpretation of scores, evident in DOPPS (6). Fifth, application and implications represented here pertain to groups of patients, and the role of SF-12 component scores as an adjunct to clinical decision making in individual patients require further investigation. We need longitudinal studies in individual patients that can also assess the sensitivity of SF-12 measurements to changes in clinical condition and interventions as well as the potential for patient fatigue or “burnout” with repeated periodic survey administration. Finally, potential “context” bias may arise from our use of the embedded SF-12 (within the SF-36) as opposed to isolated implementation of the SF-12 questionnaire; however, some reassurance may be gained from a study conducted by Ware *et al.* (30) in a sample of 525 patients for whom the product moment correlation between answers to isolated SF-12 questions and the SF-12 items embedded in the SF-36 was exceptionally high ($r = 0.999$).

Conclusions

This study validates the use of the SF-12 alone or as part of a bigger survey (*e.g.*, KDQoL-36) in long-term dialysis patients. Both PCS-12 and MCS-12 correlated with those from SF-36 and have identical prognostic association with death and hospitalization risk. Norms and other interpretation guidelines from previous work using the SF-36 PCS and MCS in the US dialysis population will be applicable in interpreting the SF-12 moving forward. Further study is needed to determine utility of longitudinal SF-12 measurements with regard to responsiveness to specific clinical, situational, and interventional or therapeutic changes not only in patient groups but also within individual patients who are on long-term dialysis.

Acknowledgments

A previous version of this work was published as an abstract (*J Am Soc Nephrol* 19: 289A, 2008).

We thank Dr. Fred Finkelstein for providing a wonderful overview of the state of the science of evaluating health-related QoL for our research team. We are grateful to FMCNA social workers for diligently attempting to collect QoL information from our dialysis patients. We also thank Norma Ofsthun and Lori Vienneau for sharing their automated SF-36 scoring algorithm (in SAS) that has been used extensively in previous FMCNA projects.

Disclosures

All authors are employees of Fresenius Medical Care North America.

References

1. Ware JE, Snow KS, Kosinski M, Gandek B: *SF-36 Health Survey Manual and Interpretation Guide*, Boston, The Health Institute, New England Medical Center, 1993
2. DeOreo PB: Hemodialysis patient-assessed functional health status predicts continued survival, hospitalization, and dialysis-attendance compliance. *Am J Kidney Dis* 30: 204–212, 1997
3. Diaz-Buxo JA, Lowrie EG, Lew NL, Zhang H, Lazarus JM: Quality-of-life evaluation using Short Form 36: Comparison in hemodialysis and peritoneal dialysis patients. *Am J Kidney Dis* 35: 293–300, 2000
4. Kalantar-Zadeh K, Kopple JD, Block G, Humphreys MH: Association among SF36 quality of life measures and nutrition, hospitalization, and mortality in hemodialysis. *J Am Soc Nephrol* 12: 2797–2806, 2001
5. Lowrie EG, Curtin RB, LePain N, Schatell D: Medical outcomes Study Short Form-36: A consistent and powerful predictor of morbidity and mortality in dialysis patients. *Am J Kidney Dis* 41: 1286–1292, 2003
6. Mapes DL, Bragg-Gresham JL, Bommer J, Fukuhara S, McKeivitt P, Wikstrom B, Lopes AA: Health-related quality of life in the Dialysis Outcomes and Practice Patterns Study (DOPPS). *Am J Kidney Dis* 44: 54–60, 2004
7. Wu AW, Fink NE, Marsh-Manzi JV, Meyer KB, Finkelstein FO, Chapman MM, Powe NR: Changes in quality of life during hemodialysis and peritoneal dialysis treatment: Generic and disease specific measures. *J Am Soc Nephrol* 15: 743–753, 2004
8. Merkus MP, Jager KJ, Dekker FW, Boeschoten EW, Stevens P, Krediet RT: Quality of life in patients on chronic dialysis:

- Self-assessment 3 months after the start of treatment. The Necosad Study Group. *Am J Kidney Dis* 29: 584–592, 1997
9. Mittal SK, Ahern L, Flaster E, Maesaka JK, Fishbane S: Self-assessed physical and mental function of haemodialysis patients. *Nephrol Dial Transplant* 16: 1387–1394, 2001
 10. Morsch CM, Goncalves LF, Barros E: Health-related quality of life among haemodialysis patients: Relationship with clinical indicators, morbidity and mortality. *J Clin Nurs* 15: 498–504, 2006
 11. Lopes AA, Bragg-Gresham JL, Goodkin DA, Fukuhara S, Mapes DL, Young EW, Gillespie BW, Akizawa T, Greenwood RN, Andreucci VE, Akiba T, Held PJ, Port FK: Factors associated with health-related quality of life among hemodialysis patients in the DOPPS. *Qual Life Res* 16: 545–557, 2007
 12. Spiegel BM, Melmed G, Robbins S, Esrailian E: Biomarkers and health-related quality of life in end-stage renal disease: A systematic review. *Clin J Am Soc Nephrol* 3: 1759–1768, 2008
 13. Beusterien KM, Nissenson AR, Port FK, Kelly M, Steinwald B, Ware JE Jr: The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. *J Am Soc Nephrol* 7: 763–773, 1996
 14. Plantinga LC, Fink NE, Jaar BG, Huang IC, Wu AW, Meyer KB, Powe NR: Relation between level or change of hemoglobin and generic and disease-specific quality of life measures in hemodialysis. *Qual Life Res* 16: 755–765, 2007
 15. Ware J Jr, Kosinski M, Keller SD: A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. *Med Care* 34: 220–233, 1996
 16. Ware JE, Kosinski M, Keller SD: *SF-36 Physical and Mental Health Summary Scales: A Users' Manual*, 2nd Ed., Boston, The Health Institute, New England Medical Center, 1994
 17. Gandek B, Ware JE, Aaronson NK, Apolone G, Bjorner JB, Brazier JE, Bullinger M, Kaasa S, Leplege A, Prieto L, Sullivan M: Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: Results from the IQOLA Project. International Quality of Life Assessment. *J Clin Epidemiol* 51: 1171–1178, 1998
 18. Resnick B, Nahm ES: Reliability and validity testing of the revised 12-item Short-Form Health Survey in older adults. *J Nurs Meas* 9: 151–161, 2001
 19. Hurst NP, Ruta DA, Kind P: Comparison of the MOS Short Form-12 (SF12) health status questionnaire with the SF36 in patients with rheumatoid arthritis. *Br J Rheumatol* 37: 862–869, 1998
 20. Pickard AS, Johnson JA, Penn A, Lau F, Noseworthy T: Replicability of SF-36 summary scores by the SF-12 in stroke patients. *Stroke* 30: 1213–1217, 1999
 21. Muller-Nordhorn J, Roll S, Willich SN: Comparison of the Short Form (SF)-12 health status instrument with the SF-36 in patients with coronary heart disease. *Heart* 90: 523–527, 2004
 22. Eustace JA, Coresh J, Kutchey C, Te PL, Gimenez LF, Scheel PJ, Walser M: Randomized double-blind trial of oral essential amino acids for dialysis-associated hypoalbuminemia. *Kidney Int* 57: 2527–2538, 2000
 23. Curtin RB, Sitter DC, Schatell D, Chewing BA: Self-management, knowledge, and functioning and well-being of patients on hemodialysis. *Nephrol Nurs J* 31: 378–386, 396, 2004
 24. Gorodetskaya I, Zenios S, McCulloch CE, Bostrom A, Hsu CY, Bindman AB, Go AS, Chertow GM: Health-related quality of life and estimates of utility in chronic kidney disease. *Kidney Int* 68: 2801–2808, 2005
 25. National Kidney Foundation: I. NKF-K/DOQI clinical practice guidelines for hemodialysis adequacy: Update 2000. *Am J Kidney Dis* 37: S7–S64, 2001
 26. Gotch FA: Evolution of the single-pool urea kinetic model. *Semin Dial* 14: 252–256, 2001
 27. KDQoL Work Group: Scoring the KDQoL-36: kdqol36.sas. KDQoL Website hosted by UCLA. Available at: <http://gim.med.ucla.edu/kdqol/downloads/download.html>. Accessed February 15, 2008
 28. Mapes DL, Lopes AA, Satayathum S, McCullough KP, Goodkin DA, Locatelli F, Fukuhara S, Young EW, Kurokawa K, Saito A, Bommer J, Wolfe RA, Held PJ, Port FK: Health-related quality of life as a predictor of mortality and hospitalization: The Dialysis Outcomes and Practice Patterns Study (DOPPS). *Kidney Int* 64: 339–349, 2003
 29. Hamilton TE: Memorandum S&C-09-01: *End Stage Renal Disease Program Interpretative Guidance Version 1.1* (Advance Copy), Baltimore, MD, Center for Medicaid and State Survey Operations/Survey & Certification Group, Centers for Medicare and Medicaid Services, Department of Health and Human Services, October 3, 2008
 30. Ware JE, Kosinski M, Keller SD: *SF-12: How to Score the SF-12 Physical and Mental Health Summary Scales*, 3rd Ed., Lincoln, Quality Metrics Inc., 1998